From suppressor to enhancer: IL-10’s alternative role in CAR-T cell therapies against solid tumors

Aiming to improve the effector function of CAR-T cells, Zhao et al.1 report that IL-10 metabolically reprograms CAR-T cells, and this promotes their effectiveness against solid tumors and challenges IL-10's perceived role as merely immunosuppressive. This simple but promising strategy fosters durable immune memory and eagerly awaits validation in clinical trials.